Trial · NCT00902291
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
NCT00902291, Phase 2, Completed, Astellas Pharma Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer. Trials, record NCT00902291. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00902291
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
- NCT number
- NCT00902291
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 205 participants, actual
- Lead sponsor
- Astellas Pharma Inc
- Conditions
- Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease
- Interventions
- AGS-1C4D4, Gemcitabine
- First posted
- 2009-05-15
- Last updated
- 2015-09-14
- Other registries' IDs
- eudract:2009-009194-99
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival rate at 6 months | 6 months | |
| Secondary | Overall Survival (OS) | Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study | |
| Secondary | Progression free survival (PFS) | Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study | |
| Secondary | Change in level of serum tumor marker CA 19-9 | Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period | |
| Secondary | Incidence of anti-AGS-1C4D4 antibody formation | Week 1, Week 7 and every 8 weeks during the extended treatment period | |
| Secondary | Objective Response Rate (Partial Response or better per RECIST criteria version 1.1 | Week 8, and every 8 weeks during the extended treatment period | |
| Secondary | Disease Control (Stable Disease or better per RECIST criteria) | Week 8, and every 8 weeks during the extended treatment period |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23448807 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00902291
GET https://conductscience.org/api/trials/v1/NCT00902291/registered